Project Description
The patents used in C-103, a reformulation of Orlistat that helps minimize and reduce the negative side effects of the popular weight loss drug.
US Patent 7,662,373: “Method and composition of a medicament to decrease the adverse events of Orlistat, an oral lipase inhibitor”
US Patent 8,110,186: “Method to maintain the efficacy of Orlistat”
US Patent Application 15/279,773: “Dual Compartment Capsule for the Administration of Orlistat”
ABOUT CALLITAS
As a company, our number one goal is helping people by bringing products to market that improve quality of life. All our drug treatments and biomedical technologies fit our mission to deliver breakthrough products and services that reduce invasiveness and enhance daily living.
INVESTOR INQUIRIES
- 1.859.868.3131
investors@callitas.com
- 187 Pavilion Parkway
Suite 200
Newport, Kentucky 41071
PRESS AND MEDIA INQUIRIES
pressroom@callitas.com